Zebrafish models enhance hit-to-lead optimization, accelerating early drug development with high-throughput screening.

Optimize drug discovery pipelines with zebrafish high-throughput screening. Discover automation, robotics & phenotypic screening solutions.

The Drug Discovery and Development Process: Context and Functions

Exploring how zebrafish screening transformed cardiomyopathy drug development, reducing costs and accelerating timelines

Accelerating Drug Development with Zebrafish Models

Advancing Drug Discovery with Zebrafish High-Content Screening

Discover how zebrafish accelerate early-stage screening, enhance predictive insights, and reduce costs in drug development

Is the Traditional Drug Discovery Process Holding Back Your Pipeline?

The Impact of AI on Pipelines, Productivity, and Clinical Success

How Does ZeClinics Take Advantage of Data Science?

Leveraging Relationships in Knowledge Graphs to Enhance Drug Discovery and Target Identification

Readily assess visual function in a live organism

Harness the potential of our new Zebrafish-Based Platform for High-Throughput Gene Target Validation and Drug Screening in F0

The United States approves technological alternatives to reduce animal testing

Zebrafish contribution to drug development reaching clinical stages

AI can address many challenges and limitations in traditional R&D and offer value in drug discovery in multiple ways.

Why zebrafish can pave the way for investigating epilepsy’s etiology and screening new anti-seizure drugs

How to choose which type of experiment is best-suited for my research?

Leveraging zebrafish to study Age-related Macular Degeneration

The emerging use of zebrafish to model metabolic diseases

Are zebrafish suitable for human drug discovery?

Zebrafish represents a key tool to boost drug discovery by enabling phenotypic screening approach in pharmacological-based disease models.

ZeClinics can do it by using different genome editing approaches.

ZeClinics laboratory R&D efforts are mainly divided in the development of three research platforms including a number of research areas.

We knew the model was brilliant for academic research. Would it be as good for modeling human disease and discovering new drugs in an industrial setting?